Akero Therapeutics, Inc. - AKRO STOCK NEWS

Akero Therapeutics (Nasdaq: AKRO) announced that Tim Rolph, Chief Scientific Officer and Co-Founder, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 12:00 p.m. (ET). The presentation will be available via a live webcast on the company's investor relations website. Akero is focused on developing treatments for non-alcoholic steatohepatitis (NASH), with its lead candidate, efruxifermin (EFX), currently undergoing a Phase 2b clinical trial. EFX offers a promising treatment approach for this complex disease.

Akero Therapeutics (Nasdaq: AKRO) will present at the Morgan Stanley Virtual Global Healthcare Conference on September 15, 2021, at 11:45 a.m. (ET). The presentation will highlight the company's innovative approach to treating non-alcoholic steatohepatitis (NASH) with its investigational drug, efruxifermin (EFX). EFX aims to offer potential benefits as a best-in-class medicine, with ongoing Phase 2b trials evaluating its effectiveness in patients with varying fibrosis stages. A live webcast of the presentation will be available on Akero's investor relations website.

Akero Therapeutics (Nasdaq: AKRO) reported its Q2 2021 financial results, highlighting the ongoing development of efruxifermin (EFX) for treating non-alcoholic steatohepatitis (NASH). The company has initiated a second Phase 2b clinical trial for late-stage cirrhotic NASH patients, following significant progress in previous trials, including a published study demonstrating fibrosis regression. As of June 30, 2021, Akero's cash and marketable securities totaled $230 million, expected to support operations through Q3 2023. R&D expenses rose to $24 million, reflecting increased costs related to EFX programs.

Akero Therapeutics (Nasdaq: AKRO) announced the appointment of Judy Chou, Ph.D., to its board of directors as an independent director. Dr. Chou brings 25 years of biotech experience, including roles at Bayer Pharmaceuticals and AltruBio, where she managed drug development and biomanufacturing. Her strategic insights are expected to aid Akero’s lead drug, efruxifermin, which is in a Phase 2b clinical trial for non-alcoholic steatohepatitis (NASH). This appointment reflects Akero's commitment to advancing innovative therapies in a critical therapeutic area.

Akero Therapeutics announced the publication of results from its Phase 2a BALANCED trial of efruxifermin (EFX) in the treatment of non-alcoholic steatohepatitis (NASH), showing significant reductions in liver fat and improvement in fibrosis after just 16 weeks of treatment. In the study, 48% of EFX patients normalized liver fat levels versus 5% in the placebo group. EFX demonstrated improved metabolic markers and was generally well tolerated, with minimal serious adverse events reported. The trial results contribute to the development of potentially groundbreaking NASH therapies.

Akero Therapeutics (Nasdaq: AKRO) announced new analyses from its Phase 2a BALANCED study, which evaluates efruxifermin (EFX) for treating non-alcoholic steatohepatitis (NASH). Presented at the American Diabetes Association's 81st Scientific Sessions, findings show EFX significantly improves glucose metabolism and insulin sensitivity in NASH patients with type 2 diabetes. Additionally, increased adiponectin levels correlate with better liver health. Akero's ongoing studies suggest EFX may uniquely address metabolic dysregulation in NASH, positioning it as a promising treatment option.

Akero Therapeutics (AKRO) announced significant findings from its Phase 2a BALANCED study of efruxifermin (EFX) for treating non-alcoholic steatohepatitis (NASH). Presented at the 2021 International Liver Congress, analyses reveal that a liver fat reduction of ≥17 U/L, coupled with normalizing liver fat, enhances the predictive power for NASH resolution. Key results show 69% of patients on 28mg EFX achieved ≥50% liver fat reduction, and 53% normalized liver fat by week 12. The company’s ongoing Phase 2b trials further explore EFX's potential in advanced fibrosis patients.

Akero Therapeutics (Nasdaq: AKRO) will present results from its Phase 2a BALANCED study at the 2021 EASL Congress on June 26, showcasing efruxifermin (EFX) improvements in NASH patients with compensated cirrhosis. Additionally, two presentations will occur at the 81st ADA Meeting from June 25-29. Akero emphasizes EFX's potential to reverse liver injury, improve glycemic control, and enhance lipoprotein profiles. With ongoing Phase 2b trials, the company aims to address the unmet medical needs in NASH, particularly for patients with type 2 diabetes.

Akero Therapeutics (Nasdaq: AKRO), a biotech firm focused on cardio-metabolic therapies, will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. (ET). The company is developing treatments for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Its lead candidate, EFX, is undergoing a Phase 2b clinical trial named HARMONY, targeting NASH patients with F2/F3 fibrosis. Akero is based in South San Francisco. For more details, visit www.akerotx.com.